Kazia Therapeutics (KZIA) Receivables (2017 - 2025)

Kazia Therapeutics (KZIA) has disclosed Receivables for 6 consecutive years, with $62762.5 as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Receivables fell 97.56% year-over-year to $62762.5, compared with a TTM value of $62762.5 through Jun 2025, down 97.56%, and an annual FY2025 reading of $63516.7, down 97.51% over the prior year.
  • Receivables was $62762.5 for Q2 2025 at Kazia Therapeutics, down from $2.6 million in the prior quarter.
  • Across five years, Receivables topped out at $2.6 million in Q2 2024 and bottomed at $28071.1 in Q2 2023.
  • Average Receivables over 4 years is $688220.8, with a median of $78296.8 recorded in 2025.
  • The sharpest move saw Receivables soared 9048.96% in 2024, then plummeted 97.56% in 2025.
  • Year by year, Receivables stood at $93831.2 in 2022, then crashed by 70.08% to $28071.1 in 2023, then skyrocketed by 9048.96% to $2.6 million in 2024, then plummeted by 97.56% to $62762.5 in 2025.
  • Business Quant data shows Receivables for KZIA at $62762.5 in Q2 2025, $2.6 million in Q2 2024, and $28071.1 in Q2 2023.